Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 8/20 | 0.52 |
| ▸ | CDK2 | P24941 | 7/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20502510 | 1.00 | CHEK1 (0.52) | CHEK1CDK2CCNA2CCNA1HRH3 | |
| SCHEMBL23292181 | 0.90 | HRH3 (0.53) | CHEK1CDK2CCNA2CCNA1HRH3 | |
| SCHEMBL1270087 | 0.81 | HRH4 (0.49) | HRH3HRH4 | |
| SCHEMBL28317093 | 0.81 | HRH4 (0.44) | HRH3HRH4 | |
| SCHEMBL15587845 | 0.81 | MAP3K12 (0.54) | CHEK1CDK2CCNA2CCNA1MAP3K12 | |
| SCHEMBL20292302 | 0.80 | HRH4 (0.57) | CDK2HRH3HRH4CDK1ROCK2 | |
| SCHEMBL1334272 | 0.80 | HRH4 (0.47) | HRH3HRH4 | |
| SCHEMBL29515034 | 0.79 | CHEK1 (0.43) | CHEK1CDK2CCNA2CCNA1HRH3 | |
| SCHEMBL23612242 | 0.78 | CHEK1 (0.52) | CHEK1CDK2CCNA2CCNA1MAP3K12 | |
| SCHEMBL29988658 | 0.78 | CHEK1 (0.52) | CHEK1CDK2CCNA2CCNA1MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | CHEK1 1068/4885CDK2 44/4885CCNA2 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.